-- Histobiolab, the division of Creative Bioarray, is dedicated to developing unique technologies that provide global scientists with high-quality products and satisfactory services to facilitate the investigation of life science research. Intending to help our customers accelerate life sciences research, Histobiolab announced the release of its flagship Fluorescence In Situ Hybridization service to support research in the fastest-growing areas, such as cancer diagnosis and gene-related research.
Creative Bioarray has significantly expanded and upgraded its Fluorescence In Situ Hybridization (FISH) service platform, now covering a wide range of sample types, including paraffin-embedded, non-paraffin-embedded, and tissue microarrays. This platform is dedicated to providing researchers and clinicians with more comprehensive and cutting-edge solutions for in-depth exploration of cancer genomics and disease mechanisms.
Fluorescence in situ hybridization (FISH) is a powerful cytogenetic technique that enables the visualization and analysis of specific DNA sequences within cells. Creative Bioarray leverages this cutting-edge technology to reveal the genetic landscape of cancer for its clients. Our core service accurately analyzes cancer-related gene copy number changes, helping researchers efficiently identify key genetic variants such as gene amplification and deletion, which is crucial for elucidating the complex genetic basis of various malignancies.
Highlights of Histobiolab's service upgrades include:
Histobiolab's upgraded FISH platform offers a powerful suite of multi-dimensional analytical capabilities. First, in gene copy number analysis, we can precisely quantify the copy number of oncogenes and tumor suppressor genes, accurately identifying gene amplification or deletion events that are closely linked to tumor development, progression, and drug resistance.
Second, the platform excels in DNA sequence and gene mapping, enabling precise mapping of insertion sites of specific DNA sequences, genes, or transgenes. This is crucial for gaining a deeper understanding of how genetic modifications influence tumor behavior and treatment response in animal models.
Finally, for preclinical research, Histobiolab's xenograft and chimeric model analysis services rapidly and accurately identify the presence of cross-species cells in models, providing a critical validation tool for evaluating the in vivo efficacy and mechanism of action of novel cancer therapies.
Creative Bioarray is committed to delivering accurate and reliable experimental data and ensuring that customers can fully understand the underlying meaning of their data. "We understand that accurate genomic information is key to conquering cancer," said Hannah Cole, Creative Bioarray's Director of Marketing. "This comprehensive upgrade to our FISH services demonstrates our commitment to providing cutting-edge tools to the research community. We hope to help researchers accelerate the transition from basic research to clinical applications through higher-precision analysis."
About Creative Bioarray
With an unwavering commitment to excellence and customer satisfaction, Creative Bioarray continues to innovate and expand its service offerings to meet the evolving needs of researchers and healthcare institutions. We sincerely invite researchers, clinical laboratories, and pharmaceutical companies to explore our enhanced FISH service platform and learn how Creative Bioarray can help you achieve your research goals. Creative Bioarray is a leading life science service provider specializing in genomics and molecular biology. With innovation and quality at our core, we offer a broad range of technical services and solutions to support researchers worldwide in their journey of scientific exploration and discovery.
Contact Info:
Name: Hannah Cole
Email: Send Email
Organization: Histobiolab | Creative Bioarray
Address: Shirley, NY 11967, USA
Phone: 16313868241
Website: https://www.histobiolab.com/
Release ID: 89167772
Google
RSS